Ainos Inc - AIMD STOCK NEWS

Ainos (NASDAQ: AIMD, AIMDW), a healthcare company specializing in AI-powered point-of-care testing and VELDONA low-dose interferon therapeutics, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place both in-person at the Lotte New York Palace Hotel and virtually on September 9-10, 2024.

Key highlights:

• Ainos will conduct one-on-one meetings during the conference
• Mr. Jack Lu, Director of Corporate Development, will deliver a live presentation on September 10, 2024, at 4 p.m.
• The company invites shareholders and interested parties to learn about their journey towards becoming 'AI's nose' capable of digitizing smell
• Interested attendees can register for the conference through the HCW Events website

Ainos, Inc. (NASDAQ:AIMD) is making significant strides in AI-powered smell digitization technology. CEO Chun-Hsien Tsai highlighted key achievements and upcoming milestones in a shareholder letter:

1. AI Nose Technology: Ainos is developing AI-powered digital nose sensors for healthcare and smart factories.

2. Healthcare Applications: The next-gen Ainos Flora, targeting women's health and STI testing, is set for clinical trials in Q4 2024.

3. Elderly Care: Collaborating with Nisshinbo Micro Devices and Taiwan Inabata Sangyo, Ainos aims for pilot production in Q4 2024.

4. Smart Factories: AI Nose achieved 79% accuracy in identifying VOCs in semiconductor factories, with pilot production ready in Q4 2024.

5. IP Portfolio: Ainos secured exclusive licenses for 10 multi-region patents related to gas sensors and medical device technologies.

Ainos (NASDAQ: AIMD) has unveiled a breakthrough in its AI Nose technology, achieving 79% accuracy in identifying 761 samples across 22 volatile organic compounds (VOCs) in Japanese semiconductor manufacturing factories. This advancement significantly enhances smart manufacturing factory automation and safety. The AI Nose can detect manufacturing process contamination, ensure health and safety, prevent fires, and optimize gas sensing with real-time feedback.

Ainos plans to integrate AI Nose into smart factory robotics systems, equipping robots with a human-like sense of smell to improve collaboration with workers and enhance safety. This development expands AI Nose's applications beyond medical uses into the industrial sector, positioning Ainos as a leader in VOC sensing technology.

Ainos Inc. (NASDAQ:AIMD) announced its participation in a fireside chat with Water Tower Research on August 22, 2024, at 10:00 a.m. ET. Jack Lu, Director of Corporate Development, will present an overview of Ainos' business model, strategic priorities, and AI Nose technology platform. The discussion will cover lead pipeline products, including the low-dose IFN-α therapeutic VELDONA, and its potential in human and animal health.

The fireside chat will also address Ainos' recent earnings and financial position. This listen-only event is open for registration, and a replay will be available on the company's investor relations website. Ainos is a diversified healthcare company focusing on AI-powered point-of-care testing (POCT) and VELDONA therapeutics.

Ainos, Inc. (NASDAQ:AIMD) has secured exclusive licenses for 10 invention patents and patent applications from Taiwan Carbon Nano Technology (TCNT), its affiliate and product co-developer. The licenses, valued at approximately $5.4 million, cover gas sensors and medical devices across multiple regions including the U.S., Germany, China, Japan, and Taiwan. The all-stock licensing structure aligns TCNT's interests with Ainos shareholders while preserving cash for growth.

This strategic move is expected to strengthen Ainos' AI Nose and Point-Of-Care Testing (POCT) technologies. The company is advancing its AI Nose and POCT pipeline, including the leading volatile organic compounds (VOC) POCT candidate, Ainos Flora. Ainos is also developing a VOC sensing platform with Japanese partners and progressing on the Next-Gen Ainos Flora, which implements NVIDIA CUDA technology.

Ainos, Inc. (NASDAQ:AIMD) has prepaid its remaining convertible note financing with Lind Global Fund II LP, totaling approximately $1.67 million. The company, focused on AI-powered point-of-care testing and low-dose interferon therapeutics, maintains a robust financial runway of over 12 months after the prepayment. Ainos has recently enrolled its first subject for VELDONA®-based animal drug in treating FCGS and is developing the next-gen Ainos Flora powered by AI Nose, implementing NVIDIA CUDA. The company's CEO, Chun-Hsien Tsai, expressed gratitude for The Lind Partners' financial support and reaffirmed Ainos' commitment to building shareholder value.

Ainos (NASDAQ:AIMD) reported its Q2 2024 financial results, highlighting progress in its VELDONA® animal health initiatives. The company enrolled its first subject for an FCGS clinical study, marking a shift towards drug development in animal health. Ainos raised $9 million through convertible note financing, ensuring a 12+ month financial runway. Q2 2024 saw nominal revenues and a net loss of $3,195,022. R&D expenses increased to $1,978,756, while SG&A expenses rose to $1,044,880. The company's cash position improved to $8,014,098 as of June 30, 2024. Ainos is advancing its AI Nose technology and VELDONA® human drug candidates, aiming to maximize long-term shareholder value.

Ainos (NASDAQ:AIMD) has enrolled the first subject for its Taiwanese clinical study of VELDONA®-based animal drug in treating feline chronic gingivostomatitis (FCGS). The study aims to evaluate the safety, tolerability, and efficacy of low-dose oral interferons for FCGS treatment. With 30 subjects expected to be enrolled by end-2024, the trial report is anticipated to be finalized in Q1 2025. This milestone marks a significant step in Ainos' efforts to expand VELDONA's market and develop innovative treatments for cats with FCGS. The potential market is substantial, with an estimated 5.8 to 8.3 million cats in the U.S. affected by FCGS. The global pet dental health market is projected to reach US$9.98 billion by 2030, growing at a CAGR of 6.25% from 2023.

Ainos announces significant progress in the clinical trials of its AI Nose-powered Ainos Flora device, designed for rapid, non-invasive detection of bacterial, fungal, and common sexually transmitted infections in women. The trials, conducted at four major medical centers in Taiwan, successfully tested 75 cases, validating the AI algorithm's accuracy through real-world data incorporation and comprehensive data standardization.

Building on current trial success, Ainos aims to develop a next-gen Ainos Flora with NVIDIA CUDA, targeting Q3 for design completion and Q4 for clinical trials. The new device will feature improvements for at-home testing, addressing growing demand for decentralized healthcare solutions. The STI testing market is projected to reach $256 billion by 2028, with POCT accounting for 31%.

Ainos' ongoing innovation in AI and medical technology is supported by over 50 patents. The Ainos Flora device won the 2021 iF's Medicine/Health Design Award, highlighting its effectiveness and user-friendly design for home healthcare.